Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations.
LAMPGEN ANALYSIS
Why it matters
The decision creates a MET-targeted option for a defined metastatic lung cancer population. FDA later granted traditional approval on February 15, 2024.
What research teams should watch
Document the MET exon 14 result and assay, and capture edema and dose interruptions.
PRIMARY RECORDS